Volpara Health Technologies offers a globally used, multi-vendor suite of volumetric breast imaging products designed to improve clinical decision making and the early detection of breast cancer. It’s advanced AI software platform works with healthcare provider’s expertise to more efficiently enable a high-quality, optimised, and personalized cancer screening experience.

From the time a patient enters a clinic to the moment they obtain key results, the Volpara Breast Health Platform collects and analyses information to better understand a patient’s breast cancer risk, while also objectively evaluating image quality and workflow-improvement opportunities.

EA Fund 1, Enterprise Angels flagship fund launched in 2014 invested in Volpara (formerly Matakina), netting all EA Fund 1 investors a 2x return when the EA GP Investment Committee made the decision to selldown in May 2018.

2021 results showed an almost 60 per cent increase in revenue to just under NZ$20M. Read more here